Literature DB >> 33278615

Applying GRADE for diagnosis revealed methodological challenges: an illustrative example for guideline developers.

Tuut Mk1, Burgers Js2, Langendam Mw3.   

Abstract

OBJECTIVE: To identify challenges in the application of GRADE for diagnosis when assessing the certainty of evidence in the test-treatment strategy (diagnostic accuracy, test burden, management effectiveness, natural course, linked evidence) in an illustrative example and to propose solutions to these challenges. STUDY
DESIGN: A case study in applying GRADE for diagnosis that looked at the added value of IgE for diagnosing allergic rhinitis.
RESULTS: Evaluation of the full test-treatment strategy showed a lack of (high-quality) evidence for all elements. In our example, we found a lack of evidence for test burden, natural course and link between test result and clinical management. Overall, systematically reviewing the evidence for all elements of a test-treatment strategy is more time-consuming than only considering test accuracy results and management effectiveness. To increase efficiency, the guideline panel could determine critical elements of the test-treatment strategy that need a systematic review of the evidence. For less critical elements, a guideline panel can rely on grey literature and professional expertise.
CONCLUSION: A lack of high-quality evidence and time investment if the full test-treatment strategy is assessed create challenges in applying GRADE for diagnosis. Discussion within guideline panels about critical elements that need to be reviewed might help.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GRADE; diagnosis; evidence; guidelines; medical tests; systematic review

Year:  2020        PMID: 33278615     DOI: 10.1016/j.jclinepi.2020.11.021

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Do clinical practice guidelines consider evidence about diagnostic test consequences on patient-relevant outcomes? A critical document analysis.

Authors:  Mariska K Tuut; Jako S Burgers; Trudy van der Weijden; Miranda W Langendam
Journal:  J Eval Clin Pract       Date:  2021-09-23       Impact factor: 2.336

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.